Jasper Therapeutics (NASDAQ:JSPR) Coverage Initiated by Analysts at UBS Group

UBS Group assumed coverage on shares of Jasper Therapeutics (NASDAQ:JSPR - Free Report) in a research report report published on Thursday morning, Marketbeat.com reports. The firm issued a buy rating and a $38.00 target price on the stock.

A number of other brokerages also recently weighed in on JSPR. HC Wainwright reduced their price target on shares of Jasper Therapeutics from $60.00 to $40.00 and set a "buy" rating on the stock in a research report on Friday, January 10th. BMO Capital Markets initiated coverage on Jasper Therapeutics in a research note on Friday, December 6th. They issued an "outperform" rating and a $63.00 price target for the company. Royal Bank of Canada decreased their target price on Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating for the company in a research note on Thursday, January 9th. Finally, JMP Securities reiterated a "market outperform" rating and set a $70.00 price objective on shares of Jasper Therapeutics in a report on Monday, January 6th. Eleven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $64.44.

Jasper Therapeutics Price Performance

NASDAQ JSPR traded down $0.12 during trading on Thursday, reaching $6.08. 477,987 shares of the company's stock were exchanged, compared to its average volume of 671,338. The stock has a market capitalization of $91.21 million, a P/E ratio of -1.28 and a beta of 2.11. The business has a 50 day moving average price of $12.79 and a 200-day moving average price of $17.51. Jasper Therapeutics has a fifty-two week low of $4.55 and a fifty-two week high of $31.01.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Integral Health Asset Management LLC raised its stake in shares of Jasper Therapeutics by 85.7% during the fourth quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company's stock worth $13,897,000 after acquiring an additional 300,000 shares in the last quarter. Jefferies Financial Group Inc. purchased a new stake in Jasper Therapeutics during the fourth quarter valued at about $668,000. Deutsche Bank AG grew its stake in shares of Jasper Therapeutics by 30.0% during the fourth quarter. Deutsche Bank AG now owns 170,695 shares of the company's stock valued at $3,649,000 after buying an additional 39,436 shares during the last quarter. Braidwell LP increased its holdings in shares of Jasper Therapeutics by 47.9% in the fourth quarter. Braidwell LP now owns 714,658 shares of the company's stock worth $15,279,000 after buying an additional 231,358 shares during the period. Finally, Allostery Investments LP purchased a new stake in Jasper Therapeutics during the 4th quarter valued at about $470,000. Institutional investors own 79.85% of the company's stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.